Announcement: “Group B Neisseria Meningitidis Vaccine”

Now Available for Technology Transfer

The National Health Research Institutes (NHRI) are pleased to announce that the “Group B Neisseria meningitides vaccine” is now available for licensing and technology transfer.

Licensing details include:

1.  Certified seed bank, upstream and downstream process, and in-process quality control (QC) and product release QC test.

2.  Investigational-New-Drug dossier (IND) for phase I clinical trial, including development history, CMC, pre-clinical studies, and clinical protocol.

3.  Patents:

(1)  Surface protein of Neisseria Bacteria: U.S., R.O.C, and EU patents (owned by Centers for Diseases Control, R.O.C.; granted);

(2)  Production of Lipidated Proteins in E. coli: US and R.O.C. (pending);

(3)  Preparation and Purification of Subunit Vaccine for Neisseria Meningitidis (NM) Group B Isolates: US, R.O.C., and PCT (pending).

The evaluation for applicants involves two steps as below.

First step: Basic Information

The evaluation of the candidate company—

A.  Registration in compliance with the law of the R.O.C. or other countries if applicable;

B.  No conviction record by the law of the R.O.C. and other countries if applicable;

C.  Experiences in biopharmaceutical development;

D.  Committed to develop business in vaccine field.

‧  Please submit, either by mail, fax or e-mail, a “Vendor Qualification Form” with stamp (or signature) as Annex I before June 22, 2012.

‧  For more information please contact Ms. Judy Chen (; Fax: +886-37-583667) at Technology Transfer and Incubation Center, National Health Research Institutes, No. 35, Keyan Road, Zhunan Town, Miaoli 35053, Taiwan, R.O.C.

After the review, NHRI will inform the candidate companies within five (5) working days for a second-round review.

Second step: Proposal Review

A full proposal as Annex II is then required to submit by the applicants within the following one (1) month either by mail, fax or email to Ms. Judy Chen at Technology Transfer and Incubation Center. If necessary, NHRI may request the qualified candidates for oral presentation.

Candidates shall be evaluated by NHRI Review Committee based on the following four (4) assessment factors:

Evaluation Criteria / Score Percentage
1. Schedule and Manpower / 20%
2. R & D Funding / 25%
3. Relevant Experience in Vaccine Development for Human Use / 25%
4. Business Plan / 30%
Total / 100%